Efficacy and Safety of an Early Phase Single-bolus r-SAK for Acute Myocardial Infarction
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
As an effective treatment for acute ST-segment elevation myocardial infarction (STEMI), early
reperfusion may reduce the infarct size and improve the prognosis of patients. However, for
patients whose first medical contact to emergency percutaneous coronary intervention (PCI)
takes less than 2 hours, there is still lack of research evidence on whether thrombolytic
therapy before PCI can increase the benefits of patients.
In this prospective, multicenter, randomized, controlled, excellence clinical trial, subjects
meeting the inclusion/exclusion criteria should be randomly assigned 1:1 to the trail group
(r-SAK) or the control group (normal saline). The risk of major adverse cardiovascular events
within 1 year and bleeding events within 30 days were observed.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University